Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2012539 | Pharmacological Reports | 2009 | 7 Pages |
Abstract
SGLT2 inhibitors block glucose reabsorption in the kidneys, which prompts urinary excretion of glucose and results in lowering of its plasma levels. Although this group of medications is still under investigation, their efficacy in the treatment of type 2 diabetes mellitus (T2D) is very promising, with some of these inhibitors currently undergoing clinical trials.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Aleksandra BoÅdys, BogusÅaw OkopieÅ,